European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
In Beetroot latest panel, they delved into the essence of the Corporate Sustainability Reporting Directive (CSRD) with Klaudia Shevelyuk, Johan Löfquist, Pete Jefferson, Rana Ersgård, and Sebastian Streiffert.
The conversation covered not just what CSRD means for businesses but also the role…
Join Health Innovation Network Masterclass webinar on 13 May on how to prescribe safely for older people with guest speaker: Dr Lauren Walker, Senior Clinical Lecturer in Clinical Pharmacology and Therapeutics and Internal Medicine, University of Liverpool
Book your place here.
Attendees
Sponsors and
Exhibitors
Media
Contact us